TG THERAPEUTICS, INC. — Investor Relations & Filings
Filings indexed
1,011
across all filing types
Latest filing
2024-01-05
Director's Dealing
Country
US
United States of America
Listing
US
TGTX
TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| FORM 4 | 2024-01-05 | English | |
| Regulatory Filings 2024 | 2024-01-05 | English | |
| Regulatory Filings 2024 | 2024-01-03 | English | |
| FORM 10-Q | 2023-11-06 | English | |
| FORM 8-K | 2023-11-01 | English | |
| OWNERSHIP DOCUMENT | 2023-09-29 | English |
Browse filings by year
25 years- 2026 9 filings
- 2025 36 filings
- 2024 48 filings
- 2023 31 filings
- 2022 30 filings
- 2021 32 filings
- 2020 49 filings
- 2019 44 filings
- 2018 43 filings
- 2017 46 filings
- 2016 33 filings
- 2015 47 filings
- 2014 43 filings
- 2013 53 filings
- 2012 47 filings
- 2011 24 filings
- 2010 37 filings
- 2009 36 filings
- 2008 47 filings
- 2007 44 filings
- 2006 30 filings
- 2005 96 filings
- 2004 47 filings
- 2003 36 filings
- 2002 23 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
3 filings
| |||||
| 10629525 | FORM 4 | 2024-01-05 | English | ||
| 10629527 | Regulatory Filings 2024 | 2024-01-05 | English | ||
| 10629528 | Regulatory Filings 2024 | 2024-01-03 | English | ||
|
2023
12 filings
| |||||
| 10629529 | FORM 10-Q | 2023-11-06 | English | ||
| 10629531 | FORM 8-K | 2023-11-01 | English | ||
| 10629533 | OWNERSHIP DOCUMENT | 2023-09-29 | English | ||
| 10629535 | OWNERSHIP DOCUMENT | 2023-09-29 | English | ||
| 10629537 | OWNERSHIP DOCUMENT | 2023-09-29 | English | ||
| 10629538 | OWNERSHIP DOCUMENT | 2023-09-29 | English | ||
| 10629539 | OWNERSHIP DOCUMENT | 2023-09-29 | English | ||
| 10629540 | OWNERSHIP DOCUMENT | 2023-08-14 | English | ||
| 10629549 | 10-Q | 2023-08-04 | English | ||
| 10629551 | 8-K | 2023-08-01 | English | ||
| 10629553 | OWNERSHIP DOCUMENT | 2023-06-26 | English | ||
| 10629554 | Regulatory Filings 2023 | 2023-06-23 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
TG THERAPEUTICS, INC. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31066/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31066 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31066 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31066 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31066}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for TG THERAPEUTICS, INC. (id: 31066)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.